It is my great honour and privilege to serve as the 29th President of CINP. After a history of nearly 60 years, this is the first time that the President of CINP is from the Asian region and I feel this truly shows that CINP is the Worldwide college of neuropsychopharmacology.
CINP has consistently pursued the development of pharmacological treatment, which was a remarkable innovation in psychiatry at the time CINP was formed, for patients with mental illness. Since the foundation of CINP a number of regional Colleges have arisen and, along with our College, have matured in the traditional way of neuropsychopharmacology. Thanks to the dedicated efforts of our predecessors, CINP still successfully contributes to the development of neuropsychopharmacology. It is now time for us to be less focused on our past reputation and accomplishments and to start real revitalization toward our new mission as the Worldwide college.
Though there is a huge unmet need in the circumstance surrounding psychiatry, drug development in our field has been desperately slowing down and neuropsychopharmacology faces a crisis. CINP has to undertake its academic duties in order to contribute in a significant way to overcoming the current crisis. However, as a worldwide organization, we must also recognize there are still huge numbers of un-medicated patients with psychiatric disorders in developing regions including Asia and Africa, must confront this problem by contributing to such developing countries by providing educational programmes to regions where the benefits of appropriate pharmacological treatment have not yet been fully realized.
To achieve a significant revitalization in the treatment of mental disorders, given the current crisis situation, the only way forward is to achieve breakthrough innovations in collaboration not only with existing approaches including traditional pharmacology, molecular biology, genetic and neuroimaging, but also with interdisciplinary fields including system biology, computational neuroscience (e.g. machine learning) , data science (e.g. big data analysis) and applied neuroscience. Active contribution to development of breakthrough innovation must have the highest priority in any new mission statement adopted by CINP. Specifically, there is an urgent need to accelerate active interaction with researchers in the different fields noted above, in order to promote a climate of innovation.
As we strive to achieve these new objectives, we must harness the creativity and power of younger colleagues and especially woman scientists. New measures are needed to attract greater participation of woman and young scientists and researchers in diverse fields of the health and life sciences as members of CINP and to facilitate opportunities for effective collaboration for the development of better treatment of mental illness. Please share this link for membership application with your colleagues.
Over the next two years I will do my utmost to accomplish my duties as President based on the principles outlined. In the coming months we will share with you a number of specific initiatives as well as providing an update on the special membership drive for a significant increase in the number of new investigators and trainees, as well as women colleagues at all stages of their careers. To assist me in these challenging tasks, I would like to ask for active participation and cooperation from all our members and colleagues who devote themselves to treatment of mental illness and psychotropic drug development.
From 3rd – 7th July 2016 let us bring the fruits out of our collective efforts and share them among the colleagues at our memorable 30th Congress in Seoul to fulfil our renewed mission.
Prof Shigeto Yamawaki